Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.
Fiche publication
Date publication
février 2018
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Oral systemic corticosteroids have been used to induce remission in patients with active inflammatory bowel disease (IBD) for over 50 years; however, the wide array of adverse events (AEs) associated with these drugs prompted the development of steroid compounds with targeted delivery and low systemic bioavailability. This study assessed corticosteroids' comparative harm using network meta-analysis.
Mots clés
Crohn's disease, glucocorticosteroids, inflammatory bowel disease, network meta-analysis, systematic review, ulcerative colitis
Référence
Br J Clin Pharmacol. 2018 02;84(2):239-251